Background: Examining the TR␤1 cistrome in mouse liver is critical to understanding thyroid hormone signaling. Results: Novel mechanisms of positive versus negative regulation by biotinylated TR␤1 were identified. Conclusion: TR␤1 regulates transcription by changes in relative binding and use of preferred binding motifs. Significance: This study demonstrates that a mechanism other than differential co-regulator recruitment is involved in transcriptional regulation by TR␤1
Triiodothyronine (T3) regulates key metabolic processes in the liver through the thyroid hormone receptor, TR␤1. However, the number of known target genes directly regulated by TR␤1 is limited, and the mechanisms by which positive and especially negative transcriptional regulation occur are not well understood. To characterize the TR␤1 cistrome in vivo, we expressed a biotinylated TR␤1 in hypo-and hyperthyroid mouse livers, used ChIP-seq to identify genomic TR␤1 targets, and correlated these data with gene expression changes. As with other nuclear receptors, the majority of TR␤1 binding sites were not in proximal promoters but in the gene body of known genes. Remarkably, T3 can dictate changes in TR␤1 binding, with strong correlation to T3-induced gene expression changes, suggesting that differential TR␤1 binding regulates transcriptional outcome. Additionally, DR-4 and DR-0 motifs were significantly enriched at binding sites where T3 induced an increase or decrease in TR␤1 binding, respectively, leading to either positive or negative regulation by T3. Taken together, the results of this study provide new insights into the mechanisms of transcriptional regulation by TR␤1 in vivo.
Triiodothyronine (T3), 3 the biologic congener of thyroid hormones, regulates many aspects of mammalian physiology including neural development, growth, heart rate, thermogenesis, and metabolism. In the liver, T3 is known to affect lipid, cholesterol, carbohydrate, and amino acid metabolism, although the mechanisms by which such regulation occurs are not clear. T3 mediates its effects genomically by engaging thyroid hormone receptor (TR) isoforms that are ligand-activated transcription factors (1) . The three functional receptor isoforms that bind T3 are TR␣1 (2), TR␤1 (3), and TR␤2 (4) (reviewed in Ref. 5) , and these isoforms are expressed at different levels across various tissues. The TR␤1 isoform is predominantly expressed in the liver and is known to mediate the majority of the effects of T3 in this tissue (6) .
TRs mediate the effects of T3 by binding to thyroid hormone response elements (TREs) present in the regulatory regions of target genes. TR can bind as a monomer, as a homodimer, or as a heterodimer with retinoid X receptor (RXR) at TREs to regulate transcription (7) (8) (9) . For positively regulated genes, TR is thought to bind to the TREs in the absence of T3, repressing their transcription, whereas in the presence of T3, TR mediates activation of gene expression, and these opposing effects are mediated through differential recruitment of co-repressors and co-activators, respectively (10 -13) . Genes whose expression is negatively regulated by T3 may be regulated by TR in an opposite manner to positive target gene regulation in terms of co-activator and co-repressor recruitment (10, 14 -16) . Although it is currently thought that TR binds to its target sites in the absence or presence of ligand, it has not yet been determined whether T3 can regulate the specificity or relative affinity of TR binding to its target sites. Although a number of target genes have been identified for TR in the liver, this list is not comprehensive and does not explain all of the effects of T3. Previous studies have been based on microarray analysis of mRNA generated from T3-treated samples compared with untreated controls (17) (18) (19) (20) . This approach does not address whether the changes seen in gene expression reflect a direct effect of T3 on target genes through the TR or whether some of these changes in expression are secondary effects. TRs have been shown to bind to a variety of related sequences in vitro (21) , and TREs have been identified in several TR target genes (22) (23) (24) (25) (26) , but a comprehensive analysis of TREs on a whole genome level has not been performed. In particular, despite the identification of some negative TREs (22, 27, 28) , a consensus TRE for negative regulation has not been characterized.
A recent study analyzed the TR␣1 and TR␤1 cistromes in a neural cell line using overexpressed, tagged receptors and demonstrated that the two receptor isoforms have some overlap in binding sites but also have several unique targets (29) . A number of genes that have shared binding sites were also up-regulated by T3, and very little correlation was seen between negatively regulated genes and TR binding sites. However, no studies thus far have characterized the TR cistrome in vivo, and it is not clear whether TR binding in tissues would recapitulate results from cell culture models. To identify and characterize TR␤1 binding sites in mouse liver in an unbiased manner, we performed chromatin affinity precipitation coupled with sequencing by using a biotin-tagged TR␤1 that was expressed in mouse liver through adenoviral delivery (we refer to the method as ChIP-seq throughout the manuscript despite using affinity precipitation). Because we were unable to find commercial antibodies for TR␤1 that work well for chromatin immunoprecipitation, we chose to use a tagged TR␤1 protein and performed these experiments under both hypothyroid and hyperthyroid conditions to enable assessment of differential genomic targeting of TR␤1 in the two thyroid states. Many target sites were identified across the mouse genome with the majority of binding found within the gene body of known genes. Interestingly, T3 treatment alters TR␤1 binding both positively and negatively at distinct genomic sites, and these changes are strongly correlated with changes in expression of associated genes. ChIP peaks induced by T3 showed enrichment of a DR-4 motif and tended to be associated with positively regulated genes, whereas ChIP peaks decreased by T3 had enrichment of a DR-0 motif and were more likely to be associated with negatively regulated targets. Taken together, these results suggest a new mechanism of regulation of target genes by TR␤1, where transcriptional changes are effected by T3 dictating differential binding of TR␤1 through preferred motifs. Additionally, we also demonstrate that although the TR/RXR heterodimer may be important in induction of gene expression by T3, it is not required for the induction of all genes, and T3-mediated repression is less likely to employ the TR/RXR heterodimer.
EXPERIMENTAL PROCEDURES
Constructs and Generation of Ad-Blrp-TEV-hTR␤1 Adenovirus-The hTR␤1 cDNA was obtained from Origene, and the hTR␤1 insert was PCR-amplified and cloned into the XhoI sites of the Blrp-TEV vector (kindly provided by Dr. Christopher Glass, along with the BirA-expressing plasmid). The whole fragment containing Blrp-TEV hTR␤1 was PCR-amplified and subcloned by TA cloning into the TopoTA vector and subsequently subcloned into the Dual-GFP-CCM adenoviral shuttle vector from Vector Biolabs. The adenovirus Ad-Blrp-TEV-hTR␤1 (Ad-TR␤1) was then generated at Vector Biolabs and tested for expression in BirA-expressing mice. The GFP-expressing control virus (Ad-GFP) used in these experiments has been previously described (43) . In vivo biotinylation of proteins has been used in several previous studies, including in ChIP assays (44 -47) .
Cell Culture Experiments-293T cells were grown in DMEM with 10% FBS and maintained at 37°C in 5% CO 2 . Cells were plated in 6-well plates for Western blot experiments and in 12-well plates for reporter assay experiments. For Western blots, a total of 1 g of DNA per well was transfected using LipofecAMINE 2000 according to the manufacturer's protocol. The cells were lysed in 500 l of lysis buffer (Cell Signaling), and 5 l was used for Western blot. For streptavidin pulldown experiments, 100 l of lysate was incubated with streptavidinagarose in lysis buffer (Cell Signaling) followed by three washes in lysis buffer. Precipitates were boiled at 95°C with SDS loading buffer and electrophoresed for Western blot analysis. For reporter assays, cells were transferred to medium containing stripped serum, and a total of 0.25 g of DNA was transfected per well with the indicated amounts of each plasmid (see figure legends). Total DNA amount transfected in all wells was maintained the same by adding empty vector. After 16 h of transfection, cells were dosed with 10 nM T3 in stripped medium for 24 h. The cells were then lysed in passive lysis buffer and assayed for luciferase activity using a Luciferase assay system (Promega) and the Lumat LB9507 luminometer. Total protein was measured using a BCA assay kit (ThermoFisher Scientific).
Mouse Models and Adenoviral Injections-All mouse experiments were approved by the Institutional Animal Care and Use Committee at Beth Israel Deaconess Medical Center. Male Gt(ROSA)26Sortm1(birA)Mejr/J mice (referred to as BirA mice) were obtained from The Jackson Laboratory and crossed with female FVB mice, and the BirA line was maintained by heterozygous crosses. 9 -10-week-old male heterozygous BirA mice were housed in single cages and maintained on a low iodine propyl-thiouracil (PTU) diet for 3 weeks to render them hypothyroid. At the end of 3 weeks, mice were injected with either Ad-GFP (1 ϫ 10 9 pfu/mouse) or Ad-TR␤1 (5 ϫ 10 9 pfu/ mouse) via the tail vein. These viral loads were previously determined to result in roughly equivalent expression of GFP in both types of mice. Half of the mice in each group were given T3 injections intraperitoneally at a dose of 25 g/100 of g body weight for 4 days starting on the day of adenoviral injection to render them hyperthyroid, whereas the remaining half was given saline injections. This dose of T3 has been shown to elevate serum T3 levels significantly (11) . For each group and each treatment, n ϭ 9 -10 mice. The mice were euthanized on day 5 after adenoviral injection and the start of T3 injections, and the livers were collected and snap-frozen in liquid nitrogen. We examined each liver prior to freezing with a UV lamp to determine whether GFP expression was uniform across the whole liver and subsequently tested each liver for expression of GFP and biotinylated TR␤1 by Western blot analysis (n ϭ 9 -10/ group). For validation experiments of mRNA expression changes, we used mice that were not injected with either virus. Twenty-four C57BL6/J mice (from The Jackson Laboratory) were divided into three groups of 8 each, and 16 mice were placed on PTU diet for 3 weeks, whereas the remaining 8 were maintained on a rodent chow diet. At the end of 3 weeks, 8 mice that had been fed PTU were injected intraperitoneally with T3 (25 g/100 g) to render them hyperthyroid, whereas the remaining mice received saline.
Western Blotting and mRNA Expression Analysis-For Western blot analysis, 50 mg of liver tissue was homogenized in 1 ml of lysis buffer (Cell Signaling) with protease inhibitors and then centrifuged to remove debris. 5 l of lysate was then electrophoresed on Novex 10% Bis-Tris gels and transferred to nitrocellulose membrane. Blots were probed for biotinylated TR␤1 using streptavidin-HRP (Amersham Biosciences) and visualized using ECL-Plus (Amersham Biosciences). Blots were also probed for TR␤1 (anti-TR␤1 antibody; ThermoFisher Scientific) and GFP (anti-GFP antibody; Molecular Probes), appropriate HRP-conjugated secondary antibodies, and visualized using ECL-Plus (Amersham Biosciences). For mRNA expression analysis, 30 mg of liver was homogenized, and RNA was extracted using STAT60 (Teltest) according to the manufacturer's instructions. cDNA was generated using a cDNA kit (Advantage RT for PCR, Clontech; or Vilo Superscript, Invitrogen) and diluted for use in qPCRs. Both TaqMan and SYBR chemistries were used to quantitate gene expression (primer information available on request) using an ABI 7900HT thermocycler.
Microarray Analysis-For microarray analysis, RNA was extracted from three replicate livers for each group (Ad-GFP-PTU, Ad-GFP-PTUϩT3, Ad-TR␤1-PTU, and Ad-TR␤1-PTUϩT3) using the Perfect Pure RNA tissue kit (5 Prime). Total RNA (200 ng) was then used for GeneChip analysis. Preparation of terminally labeled cDNA, hybridization to genomewide murine Gene Level 2.0 ST GeneChips (Affymetrix), and scanning of the arrays were carried out according to the manufacturer's protocols. RMA signal extraction, normalization, and filtering were performed as described previously (11) . A variation filter was applied for selecting informative (i.e., significantly varying) genes. The filtering criteria for the exemplary data sets required an interquantile range of 0.5 and at least one sample with expression intensity of 100.
Statistical Group Comparisons for Microarray Experiments-To calculate differential gene expression between individual sample groups, we performed a statistical comparison using the limma package as described previously (11) . Briefly, limma estimates the fold change between predefined sample groups by fitting a linear model and using an empirical Bayes method to moderate the standard errors of the estimated log fold changes for each probe set (48) . A multiple testing correction based on the false discovery rate was performed to produce adjusted p values. All calculations were performed using the statistical software R.
Chromatin Immunoprecipitation Assays and ChIP-seq-We used chromatin affinity purification to capture protein-DNA complexes rather than antibody-based immunoprecipitation; however, for the purpose of this study, we have referred to the method as "ChIP-seq" rather than "ChAP-seq." For each experiment, four livers per group of mice were used (groups: Ad-GFP-PTU, Ad-TR␤1-PTU, and Ad-TR␤1-T3). 30 mg of liver was minced and cross-linked using 2 mM disuccinimidyl glutarate in PBS at room temperature for 45 min and washed in PBS. The minced liver was then cross-linked using 1% formaldehyde for 5 min, followed by 0.125 M glycine for 5 min to stop cross-linking. The cross-linked liver was then washed in PBS and manually homogenized in 10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 0.3% Nonidet P-40 with protease inhibitors. Crude nuclei were collected by centrifugation at 1,000 ϫ g; washed in PBS once; resuspended in 50 mM Tris, pH 8.0, 10 mM EDTA, 0.25% SDS with protease inhibitors; and sonicated in 1-ml AFA tubes using a Covaris sonicator to achieve a DNA shear size of 200 -500 bp. The sonicate was centrifuged to remove debris, and the chromatin from all four livers per group was combined into a single chromatin sample. Chromatin was diluted in 0.5ϫ radioimmune precipitation assay buffer with protease inhibitors and 20 g of glycogen and used for precipitation with streptavidin-agarose beads (Ther-moFisher Scientific). Following precipitation, cross-links were reversed at 65°C overnight, DNA was extracted using phenolchloroform-isoamylalcohol and ethanol-precipitated with 50 g of glycogen. For regular ChIP experiments, DNA from five replicate precipitation reactions was used in qPCRs with SYBR chemistry to detect enrichment (all primer sequences are available on request). For RXR␣ ChIP experiments, anti-RXR␣ antibody (sc-553; Santa Cruz) was used with protein A-agarose. For ChIP-seq, DNA obtained from 10 replicate precipitation reactions were combined. DNA was quantitated, and libraries were constructed for sequencing at the Dana Farber Center for Cancer Computational Biology. Libraries were prepared using the using the NEBNext ChIP-Seq Library Prep Master Mix Set for Illumina according to the manufacturer's protocol (New England Biolabs). Sequencing libraries then went through a quality control process including the Qubit fluorometer (Invitrogen), the Agilent Bioanalyzer (high sensitivity chip), and qPCR using the KAPA Biosystems library quantitation kit for Illumina on an ABI 7900HT Fast instrument. Libraries were sequenced on an Illumina HiSeq2000 on a Single Read 50-cycle flow cell.
ChIP-seq Analysis-Sequencing reads were mapped to the mm9 reference genome using Bowtie (49) , and peaks were called using MACS2 (50) with standard thresholds with a q value of Ͻ0.01 (reduced stringency peaks) or p value of 1e Ϫ19 (high stringency peaks). To compare peaks in response to T3, significantly enriched regions from individual treatments were merged to provide a set of comparable genomic regions for which ChIP-Seq reads were recounted for each treatment using Bedtools coverage v2.16.1 program (51) . Regions that showed differences in TR␤1 enrichment were identified using the edgeR algorithm (52) . Regions with a p value of Ͻ0.05 after Bonferroni correction for multiple hypothesis testing were determined to be differentially enriched by T3. Invariant peaks were defined as those peaks from the edgeR analysis that had p Ͼ 0.5. Peaks were assigned to different genomic regions of associated target genes as described under "Results." RXR ChIP peak (33) and DNase hypersensitivity peak (available through the mouse ENCODE project) overlap were determined using custom scripts. For correlation of gene expression changes with differential peaks, we used the microarray data from Ad-TR␤1-PTU versus Ad-TR␤1-T3. To obtain a list of genes that were regulated by T3 and also had proximal TR␤1 ChIP peaks (see Fig. 3 ), we selected both robust ChIP peaks at a high p value threshold of e Ϫ50 and genes with robust expression changes (at least 2-fold and p Ͻ 0.05).
Motif Analysis-For each set of peaks of interest, a 300-bp central sequence was evaluated for motif instances using FIMO (53) with the TRANSFAC vertebrate nonredundant miniFP motif database as of 2012 and default parameters other than using only high quality matrices (54, 55) . Motifs were enumerated for 1) the regions corresponding to the specific peaks of interest and 2) a background set of 2,000 randomly selected DNase hypersensitivity peaks. Enrichment scores for each motif and species were then defined as the number of instances detected in the specific peaks of interest divided by the number of instances detected in each set from the hypersensitivity peaks. We applied Fisher's exact test to calculate significant enrichment or depletion. For relative enrichment of DRs, everted repeats, and inverted repeats, we applied above matching algorithm with DR motif provided by Hua et al. (56) , using 200 bp of central peak sequences.
For de novo motif discovery, we applied GLAM2 (57) to 200-bp central regions in various peak sets of interest without allowing for insertions or deletions. We report the top-scoring motif in each case. Data from ChIP-seq and microarray experiments have been submitted to the GEO database. ChIP-seq data are accessible under GSE52613, and microarray data are accessible under GSE52433
RESULTS
Generation and Characterization of Bio-TR␤1 Mice-To express a biotinylated TR␤1 (Bio-TR␤1), we generated a construct that expressed human TR␤1 with a Biotin ligase recognition peptide (Blrp) sequence tag upstream of the TR␤1 cDNA sequence. The Blrp sequence is recognized by the bacterial biotin ligase BirA, which then biotinylates the fusion protein. This construct was initially tested in 293T cells for expression, biotinylation, and transcriptional activity and was found to be functional and achieve similar transcriptional activity to the wildtype receptor (Fig. 1A) . To express this biotinylated TR␤1 in mouse liver, we generated an adenovirus (Ad-TR␤1) that coexpressed the Blrp-TR␤1 with GFP ( Fig. 1B ) or a control virus that expressed only GFP (Ad-GFP) and injected BirA-expressing mice via the tail vein. Because we wanted to determine TR␤1 genomic binding under both hypo-and hyperthyroid conditions, BirA mice were placed on a PTU diet for 3 weeks prior to adenoviral delivery, and half the mice were given a supra-physiological dose of T3 for 4 days, starting on the day of adenoviral delivery. Bio-TR␤1 was expressed equally in the livers of BirA mice that received Ad-TR␤1 under both hypo-and hyperthyroid conditions ( Fig. 1B) as detected by streptavidin immunoblotting, whereas all mice that received either type of virus (Ad-TR␤1 or Ad-GFP) expressed GFP. We also detected TR␤1 by using a TR␤1-specific antibody and found that, as expected, TR␤1 is overexpressed in Bio-TR␤1 mice (livers from TR␤-KO mice were used as a negative control in this experiment).
To determine whether gene regulation of known TR target genes was affected in this model system, we assessed the expression of hepatic TR target genes gpd2, thrsp, fasn, bcl3, gsta2, and fbxo21 by qPCR analysis (Fig. 1C ). In the case of positively regulated genes (gpd2, thrsp, fasn, and bcl3), overexpression of TR␤1 in hypothyroid livers resulted in enhanced repression of basal expression, in agreement with the known ability of TR to mediate transcriptional repression in the absence of ligand. In the hyperthyroid state, however, there was no significant difference between Ad-GFP and Ad-TR␤1 livers, because both groups showed similar induction of gene expression. For the negatively regulated genes gsta2 and fbxo21, repression in the hyperthyroid livers was further enhanced in Ad-TR␤1 livers compared with GFP controls (Fig. 1C) . These results suggest that overexpression of TR␤1 did not disrupt normal gene regulation of known target genes by T3 in the liver.
Identification of TR␤1 Binding Sites in Mouse Liver-Livers from Ad-GFP-PTU, Ad-TR␤1-PTU, and Ad-TR␤1-T3 mice (all of which also express BirA) were used to extract chromatin, and ChIP assays were performed using streptavidin-agarose to precipitate the biotinylated TR. We were able to detect significant enrichment of a previously described site within the gpd2 promoter in Ad-TR␤1 livers under both conditions (PTU and PTUϩT3) compared with Ad-GFP livers ( Fig. 2A) by ChIP-PCR. Importantly, there was no enrichment of the control ␤-globin locus in the Ad-TR␤1 livers. We then performed ChIP-seq analysis on Ad-TR␤1 and Ad-GFP livers. Peaks were called in two separate analyses using a p value threshold of 1e Ϫ19 (high stringency peaks) or a q value threshold of 1e Ϫ01 (reduced stringency peaks). This dual analysis was performed to analyze robust peaks (high stringency) and to also allow for a more inclusive analysis of less robust peaks (reduced stringency) because this was likely to provide additional information on the relative strength of TR␤1 binding. A total of 20,939 and 15,723 peaks were called for high stringency peaks in Ad-TR␤1-PTU and Ad-TR␤1-T3 livers, respectively. Only five peaks were called in the Ad-GFP-PTU sample in this analysis. The Ad-GFP-PTU chromatin sample was used as a control because any biotinylation of endogenous proteins by BirA would be seen in these animals. Thus, these results suggest very low background in the streptavidin pulldown of Bio-TR␤1 and also indicate that any endogenous biotinylation by BirA is not an issue in this model. A total of 51,992 and 46,092 peaks were called for reduced stringency peaks in Ad-TR␤1-PTU and Ad-TR␤1-T3 livers, respectively.
Peaks were then annotated to various regions of the genome as defined: promoters (transcription start site to Ϫ500 bp), upstream (Ϫ500 bp to Ϫ10 kb), gene body (transcription start site to transcription end site), downstream (transcription end site to ϩ5 kb), and intergenic (any region that did not fall into the above categories). The distribution of ChIP peaks across the genome in hypo-and hyperthyroid livers were largely similar in both high and reduced stringency analyses (Fig. 2B) , with the majority of peaks falling within the gene body region (ϳ50%). The major difference between hypothyroid and hyperthyroid ChIP peaks was seen in the promoter and intergenic regions. Only 4% of ChIP peaks were found in the proximal promoter in hyperthyroid livers, whereas 14% of peaks were in the proximal promoter in hypothyroid livers (high stringency peaks). Conversely, a larger proportion of peaks were found in the intergenic region in hyperthyroid livers (29%) compared with hypothyroid livers (21%). This difference in distribution of ChIP peaks between hyperthyroid and hypothyroid livers was maintained in the analysis of reduced stringency peaks (7 and 17% for FIGURE 1. Validation of Bio-TR␤1 construct and generation of Ad-TR␤1 mice. A, biotinylated TR␤1 expression in 293T cells was detected by streptavidin-HRP blotting and TR␤1 immunoblotting of lysates generated from cells transfected with the expression constructs listed. Streptavidin pulldown of biotinylated TR␤1 was performed using streptavidin-agarose followed by Western blot analysis. Reporter assays were performed in triplicate in 293T cells with varying amounts of either biotinylated TR␤1 or wild-type TR␤1 using a DR4-luciferase reporter (150 ng/well). 20 ng of BirA expression vector was co-transfected to biotinylate the Blrp-TEV-TR␤1. Total DNA was maintained at 250 ng/well using empty vector. Relative luciferase activity is shown as luciferase activity normalized to total protein per well. B, schematic diagram of viral vector used to overexpress GFP and TR␤1 in mouse liver and representative Western blot analysis of Bio-TR␤1 and GFP expression in Ad-TR␤1 and Ad-GFP livers. C, mRNA expression analysis of TR␤1 target genes in the liver (n ϭ 9 -10), with expression normalized to tbp expression. *, p Ͻ 0.05; **, p Ͻ 0.01; ***, p Ͻ 0.001 as determined by t tests. IB, immunoblotting; Strep, streptavidin. promoter and 28 and 23% for intergenic, respectively), suggesting that the differences in detected binding sites between hypothyroid and hyperthyroid livers were not simply the result of eliminating peaks by using a higher stringency for peak calling in our analysis. These results suggest that T3 alters TR␤1 binding.
We next determined the overlap between TR␤1 ChIP peaks in both types of livers to DNase hypersensitivity peaks (mouse ENCODE project) to assess whether TR␤1 binds to regions of open chromatin (Fig. 2C ). 81 and 65% of TR␤1 ChIP peaks in hypothyroid and hyperthyroid livers overlap with DNase hypersensitivity peaks (high stringency peaks), and 70 and 56% of TR␤1 ChIP peaks in hypothyroid and hyperthyroid livers overlap with DNase hypersensitivity peaks (reduced stringency peaks).
Because our initial analyses suggested that T3 causes differential binding of TR␤1, we compared TR␤1 ChIP peaks (reduced stringency peaks) in hypothyroid and hyperthyroid livers using EdgeR. This analysis demonstrated that 6,585 peaks were significantly changed overall between hypothyroid and hyperthyroid livers, and of these, 19.7% were increased in hypothyroid livers, whereas 80.3% were increased in hyperthyroid livers (Fig. 2D ). We further determined a set of invariant peaks (p Ͼ 0.5 by EdgeR analysis). The genomic distribution of peaks changed by T3 is indicated by a pie chart (Fig. 2D) , and the distances of differential, invariant, and all peaks relative to the nearest transcription start site are shown in Fig. 2D . Overall, these results demonstrate a marked reduction of changed peaks in the promoter region as compared with "all" or "invariant" peaks, suggesting that T3-induced changes in TR␤1 binding more likely occur at distal enhancer elements. We also determined the overlaps between invariant peaks, differentially bound peaks, and DNase hypersensitivity peaks. 86% of invariant peaks between hypothyroid and hyperthyroid livers overlap with DNase hypersensitivity peaks, suggesting that regions of open chromatin may facilitate the binding of TR␤1 independent of T3. 70% of T3-decreased peaks, but only 27% of T3-induced peaks, overlap with DNase hypersensitivity peaks ( Fig.  2D ), suggesting that T3 allows TR␤1 to bind to less accessible regions of chromatin.
Correlation of Binding Sites to Differentially Expressed Genes-To determine whether TR␤1 binding could be correlated with gene expression changes, we performed microarray analyses on mRNA from Ad-GFP-PTU, Ad-GFP-T3, Ad-TR␤1-PTU, and Ad-TR␤1-T3 livers. To exclude changes in gene expression that were introduced by overexpression of TR␤1, only genes that were regulated by T3 in both groups of mice (i.e., hypoversus hyperthyroid Ad-GFP livers and hypoversus hyperthyroid Ad-TR␤1 livers) were considered for this initial analysis. Genes in this group that showed a robust change in expression (greater than 2-fold and p Ͻ 0.05) were identified (Fig. 3A) , and all robust ChIP peaks associated with these genes (peak threshold of p Ͻ 1e Ϫ50 , very high stringency peaks) were considered for further analyses. The choice of very high stringency peaks for this particular analysis was also based on the idea of eliminating any weak binding events that were introduced simply because of overexpression of TR␤1. Overall, there were 238 genes that were up-regulated and 291 genes that were downregulated greater than 2-fold. The number of genes regulated by Ͼ2-fold is consistent with what has been found in other microarray studies looking at T3 regulation in the liver (17, 20) . The overlap between all ChIP peaks associated with known genes (from Ϫ10 kb to transcription end site ϩ 5 kb) and Ͼ2-fold regulated genes is shown in two Venn diagrams for genes that were up-or down-regulated by T3. 72% of up-regulated genes and 39% of down-regulated genes had ChIP peaks associated with them by the criteria described. As a control, 339 genes that showed the least changes in the microarray experiment were also queried by similar analysis, and only 13% of these genes had associated TR␤1 ChIP peaks, suggesting that TR␤1 ChIP peaks are more likely to be associated with genes whose expression is regulated by T3. Gene ontology analysis was performed using the DAVID database for the genes that were regulated by T3 and that had ChIP peaks in either or both conditions as identified in the analysis in Fig. 3B (Fig. 3C ). Genes that are involved in fatty acid, lipid, steroid, carbohydrate, and amino acid metabolism were enriched in both sets of genes, whereas genes involved in small molecule transport and anti-apoptosis were enriched in the up-regulated group, and genes involved in ␤-alanine metabolism and drug metabolism were enriched in the down-regulated group (Fig. 3C ).
Because this initial analysis only identified genes that showed both robust changes in expression induced by T3 and in ChIP peaks associated with them but did not take into account ChIP peaks that are changed by T3 treatment, we next determined whether T3-induced changes in TR␤1 binding are associated with changes in gene expression. For this analysis, we compared gene expression changes between Ad-TR␤1-PTU and Ad-TR␤1-T3 livers with changes in TR␤1 binding within the genomic regions defined in Fig. 2 (differential peaks). As shown in Fig. 3D , changes in TR␤1 binding at proximal promoters induced by T3 correlated well with changes in gene expression, such that an increase in TR␤1 binding at the promoter is likely to induce increased transcription of a given gene and a decrease in TR␤1 binding results in reduced gene expression or repression. This is particularly striking given that the majority of differentially bound peaks are not located at the promoter. A similar pattern was observed for all other regions tested. Although some changes in TR␤1 binding do show inverse correlation with gene expression (Fig. 3D, top 
left quadrants and bottom right quadrants), the majority of changes in binding events show direct correlation with gene expression changes.
Validation of Binding Sites and Gene Expression Determined by ChIP-seq and Microarray Analysis-We next sought to validate changes in both gene expression and TR binding using qPCR analysis. For the gpd2 gene, a TR binding site had previ- 5) . B, distribution of ChIP peaks called at a p value threshold of e Ϫ19 (high stringency peaks) and a q value threshold of 0.01 (reduced stringency peaks) across different regions of the genome in hypothyroid (TR␤-PTU) and hyperthyroid (TR␤-T3) livers. C, overlap of high stringency and reduced stringency ChIP peaks in Ad-TR␤1-PTU and Ad-TR␤-T3 livers with DNase hypersensitivity (DHS) peaks. D, differential peak analysis in reduced stringency peaks: percentage of decreased versus increased peaks, distribution of changed peaks, location of all, changed, and invariant peaks relative to transcription start site, and overlap of changed and invariant peaks with DNase hypersensitivity peaks. TSS, transcription start site; TES, transcription end site.
FIGURE 3. Microarray analysis of gene expression in Bio-TR␤1 livers and correlation to ChIP-seq data.
A, heat map of genes regulated Ͼ 2-fold. B, overlap between ChIP peaks in hypo-and hyperthyroid livers associated with known genes and genes regulated Ͼ2-fold in microarray analysis and with genes not regulated by T3. C, GO analysis (DAVID) of regulated genes that also had ChIP peaks associated by proximity (Ϫ10 kb to transcription end site ϩ 5b). D, smooth scatter plots of differentially bound peaks versus gene expression changes for genes associated by proximity for peaks located in the different genomic regions. TSS, transcription start site. ously been characterized in the proximal promoter/first exon in rat (30) , and from ChIP-seq analysis in the current study, we were able to detect TR␤1 binding to this region in both hypoand hyperthyroid livers ( Figs. 2A and 4A ). However, our study also identified five additional sites within the gpd2 gene, of which four were found within the first intron. ChIP-qPCR was performed for all of the sites identified, and of the five new sites, four were confirmed positive (three of these sites are shown in Fig. 4A ). Interestingly, site D within the first exon was bound by TR␤1 only in the hyperthyroid livers, suggesting that even for multiple sites within a single gene, TR␤1 can bind differentially in response to T3, adding another level of complexity in regulation by TR␤1. For thrsp, three TREs located ϳ2.7 kb upstream from the transcription start site were previously identified in the rat (26) that are conserved in mouse (marked as site B in Fig. 4B ). However, ChIP-seq analyses identified three additional sites near the thrsp locus, including one site at the proximal promoter and two sites on either side of the previously identified region at approximately Ϫ6.4kb and Ϫ1.5 kb. By ChIP-qPCR, we validated TR␤1 binding at the most distal site (site A) and the proximal promoter site, both of which showed decreased TR␤1 binding in hyperthyroid livers as compared with hypothyroid livers, whereas binding at site B is consistent in both hypo-and hyperthyroid livers. dio1 is highly regulated by T3 in the liver; however, binding sites for TR␤1 have not been identified previously. Four ChIP peaks were identified in the first intron of the dio1 gene, of which two were validated (Fig.  4C) , and one of these sites (site A) showed greater enrichment in the hyperthyroid liver. These results demonstrate that for some TR target genes, multiple TR␤1 binding sites may regulate transcription and that TR␤1 binds differentially to some of these sites, depending on the absence or presence of T3. To validate additional targets that showed differential recruitment of TR␤1 and differential gene expression with T3, we analyzed the elovl6 and gys promoters. The elovl6 promoter shows increased recruitment of TR␤1, and an increase in elovl6 expression and the gys promoter shows decreased recruitment of TR␤1 and decreased expression of gys with T3 treatment (Fig. 4 , D and E, and data not shown).
We further validated several other target genes for mRNA expression by qPCR and TR␤1 binding by ChIP-qPCR ( Fig. 5) , by choosing genes that fell into one of the gene ontology groups shown in Fig. 3C . These are genes that show robust changes in gene expression as well as association with robust ChIP peaks. The purpose of these experiments was to validate both ChIPseq and microarray data; however, these analyses do not demonstrate that the ChIP peak tested is critical for expression of the associated gene. In the case of genes with multiple ChIP peaks, the highest scoring peak (lowest p value) in the TR␤1-PTU ChIP was chosen for validation. For mRNA expression analysis, a separate group of euthyroid, hypothyroid, and hyperthyroid livers that were not infected with adenovirus were used to eliminate any changes in expression that might have been driven by adenoviral infection and/or overexpression of TR␤1. For all genes tested, significant changes in expression between hypo-and hyperthyroid livers were detected. Additionally, some genes showed significant changes between euthyroid and hypothyroid livers (slc25a45, chdh, upb1, cyp2c29, and fabp2) , and most genes showed significant differences between euthyroid and hyperthyroid livers (except for cyp2c29 and fabp2). All selected ChIP peaks were validated by ChIP-qPCR. In some cases, ChIP-qPCR also demonstrated differential recruitment of TR␤1, because some sites remain consistently bound by TR␤1 between hypo-and hyperthyroid livers (ldlr, upb1, and car14), some sites show increased TR␤1 binding with T3 treatment (srebf2, pygl, cyp2c29, and fabp2), whereas others show decreased binding with T3 treatment (pnpla3, slc25s45, and chdh). Of these, chdh, srebf2, and pygl show changes in expression in the same direction as the change in TR␤1 binding, whereas cyp2c29, fabp2, pnpla3, and slc25a45 show expression in changes in an opposite direction to TR␤1 binding. Thus, whereas our global analysis shows that changes in TR␤1 binding are most often associated with changes in gene expression in the same direction, clearly there are target genes where this is not the case.
Characterization of TREs in ChIP Peaks Associated with Regulated Genes-TREs in a number of TR target genes including rat growth hormone (31) , tsh␤ (23, 27) , tsh␣ (22) , trh (28) , thrsp (26), malic enzyme (25) , and oxytocin (32) have been identified and characterized. Although these studies provide some information on the binding site for TR, a true consensus site has not been established, and a genome-wide unbiased approach would likely yield more information on the type of sequences that TR binds to. A de novo search for motifs was conducted using GLAM2, which searches for gapped motifs. An initial analysis using all peaks in both hypothyroid and hyperthyroid livers (not associated with gene expression changes) yields a TR half-site ( Fig. 6A) . A similar result was obtained upon subsequent analysis of TR␤1 ChIP peaks that were conserved between hypothyroid and hyperthyroid livers. However, when peaks that were different between hypothyroid and hyperthyroid livers were examined, a DR-4 motif (two halfsites in the same orientation separated by 4 base pairs) was enriched in peaks that were increased by T3 treatment, whereas a DR-0 motif (two half-sites, in the same orientation with no bases in between) was enriched in peaks that were decreased by T3 treatment ( Fig. 6A ).
We then interrogated the different groups of ChIP peaks specifically for DR motifs with different spacing between half-sites (DR-0 to DR-10). In this analysis, we used peaks that were associated with any change in gene expression of associated genes. We show enrichment of almost all types of DR motifs in the groups of peaks tested, compared with a background set of likely enhancers as defined by DNase hypersensitivity (Fig. 6B) . When examining all peaks, DR-4 showed the most enrichment, and when examining invariant peaks DR-4 and DR-10 showed greater enrichment. However, ChIP peaks that have significantly increased TR␤1 binding with T3 treatment show a significant increase in DR-4 enrichment, and ChIP peaks that decrease significantly with T3 treatment show significant enrichment of DR-0 ( Fig. 6B ), when associated with any change in expression of associated genes. These enrichments are maintained or even enhanced when filtering for peaks associated with parallel expression changes in the nearest gene, indicating that a DR-4 element is most commonly associated with a positive target and a DR-0 element with a negative target. Two DR0s associated with the negatively regulated genes fbxo21 (intron 9) and agxt2l1 (promoter) were validated by ChIP-qPCR, and TR␤1 binding to these sites was confirmed (Fig. 6C) . A similar analysis was performed to search for everted and inverted repeats, and although some enrichment of different types of repeats was observed, it is clear that the predominant motifs in TR␤1 ChIP peaks are of the DR type (data not shown). We also searched the TRANSFAC database for other transcription factor motifs using these sets of peaks, and a previously defined TRE was a top-scoring hit in the T3-changed groups of peaks (Table 1) . A list of the top 20 transcription factor motifs identified in each group is shown (Table 1) .
TR␤1 ChIP Peaks Overlap with RXR␣ ChIP Peaks-As outlined previously, TR␤1 can bind to DNA as a homodimer or as a heterodimer with RXR isoforms. To evaluate whether the heterodimer is the predominant active form in vivo, we used data from a RXR ChIP-seq experiment from mouse liver that was previously done using an RXR␣ antibody (33) . Importantly, the major heterodimer partner for TR in the liver is the RXR␣ isoform (34) . For this analysis, we examined higher stringency TR␤1 ChIP peaks with the unliganded RXR␣ ChIP peaks from the study by Boergesen et al. (33) . Interestingly, only 37 and 33% of TR␤1 ChIP peaks in hypothyroid and hyperthyroid livers, respectively, overlapped with RXR␣ ChIP peaks (Fig. 7A ). This suggests that a large number of TR␤1 binding sites are bound by TR␤1 as a homodimer or as a monomer. Because a number of TR␤1 binding sites were not associated with regulated genes by proximity, we then looked at the overlap of RXR␣ ChIP peaks with TR␤1 ChIP peaks associated with the regulated genes analyzed previously (Fig. 3B ). The majority of TR␤1 ChIP peaks associated with T3-up-regulated genes also overlapped with RXR␣ ChIP peaks (74% for TR␤1-PTU ChIP peaks and 81% for TR␤1-T3 ChIP peaks; see Fig. 7B ). There were relatively fewer T3-down-regulated genes that had both TR␤1 and RXR␣ ChIP peaks (41% for TR␤1-PTU ChIP peaks), which is in agreement with an earlier report that demonstrated that TR homodimers might be more important for negative regulation (35) . These FIGURE 6. Motif analysis in ChIP peaks, and ChIP peaks associated with regulated genes. A, motif search was performed using GLAM2 on ChIP peaks in the following groups: all peaks (TR␤-PTU and TR␤-T3), invariant peaks, T3-increased peaks, and T3-decreased peaks. B, distribution of different types of DR elements in the various groups of ChIP peaks. The first four rows include analysis of peaks associated with gene expression in any direction, whereas the last two rows include analysis of T3-changed peaks associated with gene expression changes in the same direction. C, ChIP-qPCR validation of DR0 elements found in the fbxo21 gene (intron 9) and agxt2l1 promoter.
results indicate that on a genome-wide level, a higher proportion of TR␤1 sites are bound as a monomer or homodimer, but at binding sites associated by proximity with regulated genes, a higher proportion of TR␤1 sites are bound as a heterodimer. The TR␤1 sites in thrsp (site A) and chdh were found to have overlapping TR␤1 and RXR␣ ChIP peaks by bioinformatic analysis, and we were able to confirm RXR␣ binding to these sites by RXR ChIP-qPCR ( Fig. 7C ). Conversely, a TR␤1 site associated with zfp810, a gene that was up-regulated by T3 in microarray analyses and confirmed by qPCR (data not shown) and that does not have a RXR␣ ChIP peak, was not bound by RXR␣ by ChIP-PCR, but it was bound by TR␤1 ( Fig. 7C ).
DISCUSSION
To determine TR␤1 binding sites in the mouse liver, we used the comprehensive, unbiased approach of ChIP sequencing. We analyzed differential TR␤1 binding in hypothyroid versus hyperthyroid livers and coupled this to microarray analyses of gene expression changes in the same livers. Our analysis demonstrates that TR␤1 binds to multiple regions across the mouse genome, with the largest percentage of binding sites found within genes (Fig. 2B ). Examination of differential TR␤1 binding in hypothyroid versus hyperthyroid livers demonstrates that many TR␤1 binding sites are bound with increased or decreased affinity, depending on the presence of ligand. A comparison of these differential peaks shows that T3-induced TR␤1 ChIP peaks show less overlap with DNase hypersensitivity peaks as compared with invariant peaks or those that decrease with T3 ( Fig. 2D) . Thus, the presence of ligand may allow TR␤1 to bind to regions of chromatin that are less open. Whether these regions become open upon TR␤1 binding remains to be tested. Importantly, changes in TR␤1 binding show a significant correlation with gene expression changes of nearby genes, which suggests that the differential recruitment of co-regulators to a stably bound TR is not necessarily the only mechanism by which T3 mediates transcriptional regulation.
To confirm differences in TR␤1 binding between hypo-and hyperthyroid livers, we examined TR␤1 binding by ChIP-PCR in three known TR␤1 target genes (gpd2, thrsp, and dio1). These genes had multiple TR␤1 ChIP peaks associated with them, including previously identified TR␤1 binding sites ( Fig.  4) . Some sites were preferentially bound in hyperthyroid livers (gpd2, site D and dio1, site A), whereas some sites showed decreased or no TR␤1 binding in hyperthyroid liver (thrsp, site A and promoter). Although it is not possible to confirm without further analyses whether these changes in TR␤1 binding alone drive transcription of the associated gene, global analysis in this study suggest that it is likely that changes in recruitment of TR␤1 itself are important for regulation of target genes. The results in Fig. 3D suggest a general pattern where changes in TR␤1 binding in the presence of T3 are likely to correspond to a change in gene expression of a nearby gene in the same direction. However, some sites/genes show a converse relationship between changes in TR␤1 binding and gene expression changes ( Fig. 5 ). When examining up-or down-regulated genes individually, we see examples where loss of repression by unliganded TR␤1 alone leads to activation, loss of activation by unliganded TR␤1 results in repression, and increased recruitment of TR␤1 can result in either activation or repression of gene expression.
The results of this work also allowed us to gain further insight into negative regulation by T3, long an area of controversy. As discussed above, we found that negative regulation could be mediated by diminished TR recruitment in the presence of T3. Furthermore, when examining ChIP peaks associated with genes that were robustly regulated by T3 in both Ad-GFP and Ad-TR␤1 livers, we found that a greater number of down-regulated genes were not associated (ϳ60%) with TR␤1 ChIP peaks as compared with up-regulated genes (ϳ27%). Thus, many negatively regulated T3 target genes could be indirect targets of TR␤1. These results are in line with those seen for TR␣1 and TR␤1 genomic binding in neural cells (29) . However, we are able to detect significantly higher association of negatively regulated genes with TR␤1 ChIP peaks than nonregulated genes (39% versus 13%); therefore our results suggest that liganded TR␤1 can function as a transcriptional repressor. This
TABLE 1 Transcription factor motifs found enriched in TR␤ ChIP peaks
For individual transcription factor (TF) motif enrichment in TR␤1 ChIP peaks, transcription factor motif frequency was assessed using sequences including Ϯ 150 bp from peak center for peaks in the various groups as indicated. is also supported by examples of individual target genes where TR␤1 binding either stays the same or increases with T3, and T3 decreases expression (upb1, car14, and fabp2; Fig. 5 ).
T3-increased peaks
Because we have only annotated ChIP peaks to genes based on proximity, it is also possible that some of the intergenic peaks identified are functional and may regulate gene expression through long range chromatin interactions. This can be delineated in a more advanced study using both chromosome conformation capture and in vivo mutation/deletion analysis. Finally, because TR can bind to DNA as a monomer, homodimer, or heterodimer with RXR␣, we looked for overlaps between TR␤1 ChIP peaks and RXR␣ ChIP peaks using data from Boergesen et al. (33) . We found that at a genome-wide level, less than 40% of TR␤1 binding sites overlapped with RXR␣ sites, but TR␤1 ChIP peaks that were associated with positively regulated genes showed a far greater overlap with RXR␣ binding sites. Therefore negative regulation by TR␤1 occurs more frequently through homodimer or monomer formation than positive regulation. Importantly, the RXR␣ ChIP in Ad-GFP livers demonstrates that RXR␣ is recruited to TR␤1 binding sites even when TR␤1 is not overexpressed, suggesting that these sites are true TR␤1 targets and not artifacts of overexpression.
To better understand genomic regulation by TR␤1, we also globally characterized its binding sites at a genome-wide level. TR␤1 has been shown to bind to two half-sites separated by FIGURE 7 . Overlap between ChIP peaks for TR␤1 and RXR. A, percentage of overlap of ChIP peaks between TR␤1 and RXR in hypo-and hyperthyroid livers. B, TR␤1 and RXR ChIP peaks associated with T3-regulated genes. Light orange circles represent regulated genes that have overlapping RXR and TR␤1 ChIP peaks, whereas light green and light yellow represent regulated genes that have only TR␤1 ChIP peaks. C, validation of RXR ChIP peaks associated with thrsp, chdh, zfp810, and the control ␤-globin locus (n ϭ 4) and validation of TR␤1 ChIP peak associated with zfp810 (n ϭ 5).
1-6 base pairs in vitro (21) , and several previously identified TREs fit this pattern. Previous ChIP-seq experiments have helped to confirm that the in vitro binding preference of nuclear receptors such as liver X receptor, glucocorticoid receptor and farnesoid X receptor are preserved in vivo (33, 36, 37) . The nuclear receptor LXR is known to bind with high affinity to DR-4 elements (38 -40) , whereas PPAR␣ binds to DR-1 elements (41, 42) , and FXR binds to IR-1 elements (36) . Because of the sensitivity of our approach, we were able to interrogate TR␤1 binding across many in vivo binding sites. Remarkably, although DR elements are enriched in all groups of peaks examined, DR-4 was globally the most enriched element. An enrichment of DR-4 was also seen in the genome-wide study by Chatonnet et al. (29) , in agreement with the results presented here. DR-4 was also most significantly enriched in T3-increased peaks associated with a gene expression change (Fig. 6B) , whereas a DR-0 was enriched in T3-decreased peaks associated with a gene expression change. Because these motif enrichments are found in peaks associated with any gene expression change as well as with parallel gene expression change, we cannot exclusively define a DR-4 as a positive TRE or DR-0 as a negative TRE. However, these results suggest the possibility that specific DR motifs provide a mechanism by which T3 can regulate TR␤1 binding and gene expression.
In summary, we have characterized the genomic binding profile of TR␤1 in hypothyroid and hyperthyroid mouse liver and demonstrate that TR␤1 can bind to different sites or with different affinities to the same sites under these two conditions to regulate transcription. The majority of the sites identified were present at enhancers within the gene body and not at promoters of known genes. Analysis of T3-dependent differential binding of TR␤1 at sites associated with regulated genes revealed that changes in TR␤1 binding correlate with changes in gene expression in the same direction, although examples of inverse correlation also occur. Motif analyses demonstrated that a DR-4 is enriched in T3-increased peaks, whereas a DR-0 is more enriched in T3-decreased peaks. Although transcriptional outcome (positive versus negative regulation) shows an association with relative TR␤1 binding and the presence of a DR-4 or DR-0 motif, respectively, it cannot be entirely distinguished by these factors or even by the presence of RXR. Still, this study gives the first insight into how the TR may mediate positive and negative regulation by employing differential binding at unique target sites. Further work should focus on how these factors work in conjunction with others, including co-activators, co-repressors, and overall chromatin context. Importantly, this work also validates the use of tagged TR␤1 and possibly other nuclear receptors in vivo, overcoming deficiencies in available antibodies for ChIP. Additionally, other isoforms of TR could also be tagged in a similar manner to be able to characterize the TR cistrome in other tissues such as the brain and heart, to further understand thyroid hormone action.
